Radiotracer
PreclinicalSmall molecule
Radiotracer is one of 109 small molecule programs targeting Sclerosing Cholangitis. It is currently in Preclinical.
3
Indications
5
Total Trials
4
Active Trials
108
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaPreclinical
HEPCLUDEX
GileadPreclinical
Farxiga
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Revia
TevaPreclinical
Cipro
BayerPreclinical
Dobutrex
Eli LillyPreclinical
Azulfidine
PfizerPreclinical
Coreg
Akero TherapeuticsPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Crohn's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Radiotracer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMassachusetts General Hospital